Cargando…

Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review

Introduction: Atopic dermatitis (AD) is a genetically based chronic inflammatory dermatosis associated with multiple triggers and complex pathophysiological mechanisms. Nowadays, an authentic therapeutic revolution is taking place with the incorporation of biological drugs for the treatment of moder...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayen-Rodríguez, Angela, Pereyra-Rodríguez, José-Juan, Navarro-Triviño, Francisco J., Alcantara-Luna, Sara, Domínguez-Cruz, Javier, Galán-Gutiérrez, Manuel, Vilar-Palomo, Samuel, Armario-Hita, Jose Carlos, Ruiz-Villaverde, Ricardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410312/ https://www.ncbi.nlm.nih.gov/pubmed/36013338 http://dx.doi.org/10.3390/life12081159

Ejemplares similares

Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis
por: Pereyra-Rodriguez, José-Juan, et al.
Publicado: (2021)

Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning
por: Alcantara-Luna, Sara, et al.
Publicado: (2022)

Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain()()
por: Pereyra-Rodriguez, Jose Juan, et al.
Publicado: (2021)

Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus
por: PEREYRA-RODRIGUEZ, Jose J., et al.
Publicado: (2023)

Study of Hypersensitivity to Malassezia furfur in Patients with Atopic Dermatitis with Head and Neck Pattern: Is It Useful as a Biomarker and Therapeutic Indicator in These Patients?
por: Navarro-Triviño, Francisco José, et al.
Publicado: (2022)

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2019)

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey
por: Sastre, Joaquín, et al.
Publicado: (2020)

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Contact Vitiligo Following Allergic Contact Dermatitis
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Sexual Dysfunction and Atopic Dermatitis: A Systematic Review
por: Linares-Gonzalez, Laura, et al.
Publicado: (2021)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Oxidative stress as a treatment target in atopic dermatitis: The role of furfuryl palmitate in mild-to-moderate atopic dermatitis
por: Hebert, Adelaide A.
Publicado: (2020)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Association of Moderate–Severe Atopic Dermatitis with Dental Anomalies
por: Tan, Sean Y., et al.
Publicado: (2022)

Bullous Allergic Contact Dermatitis Caused by Potassium Dichromate
por: Navarro-Triviño, Francisco J., et al.
Publicado: (2023)

Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
por: Hulshof, Lies, et al.
Publicado: (2018)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
por: Saporito, Rachael C., et al.
Publicado: (2016)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Herpes zóster oftálmico en el contexto de la pandemia por COVID-19
por: Ayén-Rodriguez, Angela, et al.
Publicado: (2021)

Laser Therapy for the Treatment of Actinic Cheilitis: A Systematic Review
por: Ayen-Rodriguez, Angela, et al.
Publicado: (2022)

Atopic dermatitis
por: Werfel, Thomas
Publicado: (2011)

Atopic dermatitis
por: Watson, Wade, et al.
Publicado: (2011)

Atopic dermatitis
por: Kapur, Sandeep, et al.
Publicado: (2018)

Atopic dermatitis
por: Galli, Elena, et al.
Publicado: (2020)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Evaluation of a Pseudoceramide Moisturizer in Patients with Mild-to-Moderate Atopic Dermatitis
por: Seghers, Amelie Clementine, et al.
Publicado: (2014)

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
por: Xu, Xinghua, et al.
Publicado: (2017)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
por: de Lucas, Raúl, et al.
Publicado: (2019)

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients
por: Achten, Roselie E., et al.
Publicado: (2022)

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
por: Soehoel, Anders, et al.
Publicado: (2022)

Increased Risk of Renal Malignancy in Patients with Moderate to Severe Atopic Dermatitis
por: Oh, Jongwook, et al.
Publicado: (2023)

Atopic dermatitis: allergic dermatitis or neuroimmune dermatitis?
por: Gaspar, Neide Kalil, et al.
Publicado: (2016)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate‐to‐severe atopic dermatitis
por: Puelles, J., et al.
Publicado: (2021)

Sphingosine-1-phosphate as signaling molecule in the skin: Relevance in atopic dermatitis
por: Japtok, Lukasz, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mlvor5693lsf4f655o69eibba6